NCT03810976View on ClinicalTrials.gov

A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

May 30, 2022

Study Completion Date

May 30, 2022

Conditions
Sarcoma
Interventions
DRUG

Eribulin, gemcitabine

Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks

Trial Locations (1)

03722

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03810976 - A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma | Biotech Hunter | Biotech Hunter